A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects.

Inclusion Criteria:

• Is male or female, using highly effective contraception
• Has a body mass index (BMI) 18.0 to 30.0 kg/m2, inclusive
• Is in good general health
• Having signed informed consent, is willing and able to comply with requirements of the study

Exclusion Criteria:

• Does not satisfy all screening criteria per protocol
• Is employed by or related to any personnel involved in the trial
• Has any history or condition that per protocol or in the opinion of the investigator could compromise the participant's safety or analysis of results